Citadel Advisors’s Emergent Biosolutions EBS Stock Holding History

Citadel Advisors’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$613K	Sell	73,900 -20,000	-21%	-$207K	﹤0.01%	8792
2025 Q4	$1.16M	Buy	93,900 +22,100	+31%	+$237K	﹤0.01%	7062
2025 Q3	$633K	Buy	71,800 +12,200	+20%	+$94.9K	﹤0.01%	8560
2025 Q2	$380K	Buy	59,600 +39,300	+194%	+$225K	﹤0.01%	9263
2025 Q1	$98.7K	Sell	20,300 -60,800	-75%	-$503K	﹤0.01%	11488
2024 Q4	$775K	Sell	81,100 -300	-0.4%	-$2.75K	﹤0.01%	7573
2024 Q3	$680K	Buy	81,400 +69,800	+602%	+$635K	﹤0.01%	7608
2024 Q2	$79.1K	Sell	11,600 -20,400	-64%	-$87.8K	﹤0.01%	11223
2024 Q1	$81K	Sell	32,000 -1,700	-5%	-$3.83K	﹤0.01%	11637
2023 Q4	$80.9K	Buy	33,700 +2,700	+9%	+$6.34K	﹤0.01%	11211
2023 Q3	$105K	Sell	31,000 -15,900	-34%	-$88.1K	﹤0.01%	10835
2023 Q2	$345K	Sell	46,900 -52,400	-53%	-$486K	﹤0.01%	8740
2023 Q1	$1.03M	Buy	99,300 +79,300	+397%	+$959K	﹤0.01%	6719
2022 Q4	$236K	Buy	20,000 +8,400	+72%	+$130K	﹤0.01%	9806
2022 Q3	$243K	Sell	11,600 -32,800	-74%	-$913K	﹤0.01%	10026
2022 Q2	$1.38M	Buy	44,400 +9,300	+26%	+$318K	﹤0.01%	6308
2022 Q1	$1.44M	Sell	35,100 -8,500	-19%	-$375K	﹤0.01%	6828
2021 Q4	$1.9M	Buy	43,600 +3,600	+9%	+$163K	﹤0.01%	6377
2021 Q3	$2M	Sell	40,000 -17,000	-30%	-$1.03M	﹤0.01%	6333
2021 Q2	$3.59M	Buy	57,000 +22,600	+66%	+$1.45M	﹤0.01%	5192
2021 Q1	$3.2M	Sell	34,400 -10,400	-23%	-$1.07M	﹤0.01%	5286
2020 Q4	$4.01M	Buy	44,800 +17,500	+64%	+$1.61M	﹤0.01%	4063
2020 Q3	$2.82M	Sell	27,300 -9,700	-26%	-$1.05M	﹤0.01%	4087
2020 Q2	$2.93M	Buy	37,000 +24,500	+196%	+$1.83M	﹤0.01%	3907
2020 Q1	$723K	Buy	12,500 +8,000	+178%	+$461K	﹤0.01%	5875
2019 Q4	$243K	Buy	+4,500	New	+$244K	﹤0.01%	7898
2019 Q1	–	Sell	-6,400	Closed	-$379K	–	9379
2018 Q4	$379K	Sell	6,400 -7,100	-53%	-$458K	﹤0.01%	6864
2018 Q3	$889K	Buy	13,500 +9,300	+221%	+$543K	﹤0.01%	5750
2018 Q2	$212K	Sell	4,200 -1,300	-24%	-$67.7K	﹤0.01%	7795
2018 Q1	$290K	Buy	+5,500	New	+$274K	﹤0.01%	6797
2017 Q4	–	Sell	-5,000	Closed	-$202K	–	8049
2017 Q3	$202K	Buy	+5,000	New	+$181K	﹤0.01%	6681
2017 Q1	–	Sell	-10,200	Closed	-$335K	–	7549
2016 Q4	$335K	Buy	10,200 +2,700	+36%	+$80.9K	﹤0.01%	5528
2016 Q3	$236K	Buy	+7,500	New	+$218K	﹤0.01%	6067
2016 Q1	–	Sell	-3,500	Closed	-$140K	–	7030
2015 Q4	$140K	Sell	3,500 -8,300	-70%	-$289K	﹤0.01%	6286
2015 Q3	$336K	Sell	11,800 -6,200	-34%	-$204K	﹤0.01%	5394
2015 Q2	$593K	Buy	18,000 +10,200	+131%	+$316K	﹤0.01%	4702
2015 Q1	$224K	Buy	7,800 +7,600	+3,800%	+$218K	﹤0.01%	6046
2014 Q4	$5K	Buy	+200	New	+$4.77K	﹤0.01%	8267
2014 Q3	–	Sell	-300	Closed	-$7K	–	8172
2014 Q2	$7K	Sell	300 -1,000	-77%	-$23.3K	﹤0.01%	7662
2014 Q1	$33K	Buy	1,300 +900	+225%	+$22.7K	﹤0.01%	7031
2013 Q4	$9K	Sell	400 -1,300	-76%	-$27.1K	﹤0.01%	6723
2013 Q3	$32K	Buy	1,700 +1,600	+1,600%	+$28.6K	﹤0.01%	6001
2013 Q2	$1K	Buy	+100	New	+$1.45K	﹤0.01%	6437

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Citadel Advisors's EBS Position: Q1 2026 in Review

Citadel Advisors sold out of Emergent Biosolutions (EBS) in Q1 2026, closing a stake of 232,019 shares — an estimated $2.4M sold.

Citadel Advisors first reported a position in EBS in Q2 2013 and held it in 51 quarters. The position peaked at $12.1M in Q3 2022. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

Citadel Advisors reported no remaining Emergent Biosolutions position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 232,019 Emergent Biosolutions shares in Q1 2026, an estimated $2.4M.
Citadel Advisors first reported a position in Emergent Biosolutions in Q2 2013 and held it in 51 quarters.
Citadel Advisors's Emergent Biosolutions position peaked at $12.1M in Q3 2022.
190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.